The company's lead programs include CUE-101 in phase 1b trials for HPV+ head and neck squamous cell carcinoma as both monotherapy and in combination with KEYTRUDA, and CUE-102 in phase 1b development for WT1+ colorectal, gastric, ovarian, and pancreatic cancers. Cue has collaboration agreements with LG Chem, Ono Pharmaceutical, and other partners to advance its pipeline.
Cyborg Score Rationale
Clinical-stage company with promising Phase 1b data showing tolerability and early efficacy signals (67% DCR in pancreatic cancer), but faces typical biotech risks including cash runway concerns and the uncertain path to clinical approval. Strategic partnerships with major pharma provide validation but limited near-term revenue visibility.
Top Insights
Phase 1b data shows favorable tolerability with no dose-limiting toxicities and 67% disease control rate in late-stage pancreatic cancer patients with CUE-102
Strategic collaborations with Boehringer Ingelheim, Ono Pharmaceutical, LG Chem, and ImmunoScape ($15M upfront entitlement) validate platform approach
Stock trading depressed (52-week range $0.23-$1.26) with current market cap ~$25M, indicating significant distress or valuation reset
New CEO Usman Azam appointed September 2025, signaling potential strategic repositioning
Named Competitors
CAR-T Cell Therapy — Ex vivo T cell engineering for oncology
Cell Therapy Platform — T cell therapies for cancer and autoimmune disease
T Cell Expansion Therapies — Engineered T cell therapies
Recent Developments
(December 2025) ImmunoScape collaboration and license agreement announced with $15M upfront payment entitlement
(September 2025) Usman Azam appointed President and Chief Executive Officer; Daniel Passeri transitioned to Strategic Advisor role
(April 2025) Boehringer Ingelheim strategic research collaboration and license agreement announced
(Q3 2024) Updated Phase 1 data from CUE-102 monotherapy trial showed selective WT1-specific T cell expansion and 67% disease control rate in pancreatic cancer
Open the full interactive Cue Biopharma, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.